US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Generate Biomedicines (GENB): Valuation Pushback Hits Flagship-Backed AI Biotech Company

Generate Biomedicines (GENB): Post 180-Days, From IPO Disaster to a Remarkable Recovery

Generate Biomedicines (GENB): Peeking at the IPO Prospectus of an AI Biotech Company

Generate Biomedicines (GENB): AI Biotech Sets Terms for IPO, Seeking $2.2b Valuation

IPOs and Secondary Offerings

Equity Capital Markets

Generate Biomedicines / Equity Capital Markets

<ul>
<li>AI-Driven generative biology platform aims to accelerate protein drug design, reducing development timelines and cost of proof of concept.</li>
<li>Strategic collaborations with Amgen, Novartis, MD Anderson, and Roswell Park validate platform credibility.</li>
<li>Backed by Flagship and leading institutional and tech investors, with $221.5M cash entering 2026.</li>
</ul>


AI-Driven generative biology platform aims to accelerate protein drug design, reducing development timelines and cost of proof of concept.
Strategic collaborations with Amgen, Novartis, MD Anderson, and Roswell Park validate platform credibility.
Backed by Flagship and leading institutional and tech investors, with $221.5M cash entering 2026.


Generate Biomedicines (GENB): Flagship Backed Programmable Biology Company Drawing IPO Interest